Chemoresistance, Radioresistance, and Androgen Deprivation Therapy Resistance in Prostate Cancer

Samaneh Adelian; Amin Soltani; Michael R Hamblin

doi:10.1007/978-981-97-4612-5_11

Related publications

Article2022

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Safae Terrisse, Laurence Zitvogel, Guido Guido Kroemer

Article2022

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

Safae Terrisse, Anne‐Gaëlle Goubet, Kousuke Ueda, Andrew Maltez Thomas, Valentin Quiniou, Cassandra Thélémaque, Garett Dunsmore, Emmanuel Clave, Melissa Gamat, Satoru Yonekura, Gladys Ferrere, Conrad Rauber, Hang‐Phuong Pham, Jean‐Eudes Fahrner, Eugénie Pizzato, Pierre Ly, Marine Fidelle, Marine Mazzenga, Carolina Alves Costa Silva, Federica Armanini, Federica Pinto, Francesco Asnicar, Romain Daillère, Lisa Derosa, Corentin Richard, Pierre Blanchard, Bertrand Routy, Stéphane Culine, Paule Opolon, Aymeric Silvin, Florent Ginhoux, Antoine Toubert, Nicola Segata, Douglas G. McNeel, Karim Fizazi, Guido Guido Kroemer, Laurence Zitvogel

Article2021

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Kim N., Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu,

Article2018

Results of a Phase III Trial of Optimal Sequencing of Dose Escalated Radiation (XRT) and 6 Months Androgen Deprivation Therapy (ADT) in Prostate Cancer

Shawn Malone, L. Eapen, Carter Cedric E., Wayne S. Kendal, Robert M. MacRae, George Perry, Kyle Malone, Julie Bowen, Julia Craig, Scott Grimes, Scott C. Morgan

Article2022

Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer.

Safae Terrisse, Anne‐Gaëlle Goubet, Kosuke Ueda, Andrew Maltez Thomas, Valentin Quiniou, Cassandra Thélémaque, Garett Dunsmore, Emmanuel Clave, Melissa Gamat, Satoru Yonekura, Lisa Derosa, Stéphane Culine, Paule Opolon, Florent Ginhoux, Antoine Toubert, Nicola Segata, Douglas G. McNeel, Karim Fizazi, Guido Guido Kroemer, Laurence Zitvogel

Chemoresistance, Radioresistance, and Androgen Deprivation Therapy Resistance in Prostate Cancer

Discussion(0)

Related publications

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Results of a Phase III Trial of Optimal Sequencing of Dose Escalated Radiation (XRT) and 6 Months Androgen Deprivation Therapy (ADT) in Prostate Cancer

Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer.